Skip To Main Content
Campus
Campus

Referenser

  1. Swedeheart Årsrapport 2020
  2. LaRosa JC, et al. N Engl J Med. 2005;352:1425–353.
  3. Karalis DG, et al. Cholesterol. 2012;2012:1–7
  4. Reiner Ž, et al. Eur Heart J. 2011;32:1769–18
  5. Hamilton-Craig I, et al. Vasc Health Risk Manag. 2010;6:1023–37
  6. Cannon CP, et al. N Engl J Med. 2004;350(15):1495–04
  7. Pedersen TR, et al. JAMA. 2005;294:2437–45
  8. Parker BA, et al. Circulation. 2013;127:96–103
  9. Ganga H, et al. Am Heart J. 2014;168:6–15
  10. Nordestgaard BG, et al. Eur Heart J. 2013:34;3478–90
  11. Yusuf S, et al. Lancet 2004;364:937–52
  12. Pöss J, et al. Curr Pharm Des. 2011;17:861–70
  13. Arca M, et al. Diabetes Metab Syndr Obes. 2011;4:155–66
  14. Pijlman AH. Atheros 2010;209:189–94
  15. Jernberg T, et al. Eur Heart J. 2015;36(19):1163-1170
  16. Clin Ther. 2015 Aug 14. pii: S0149-2918(15)00936-4. doi:10.1016/j.clinthera.2015.07.008. [Epub ahead of print] Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. Roth EM1, Bujas-Bobanovic M2, Louie MJ3, Cariou B4
  17. Robinson JG, et al. N Engl J Med. 2015; Apr 16;372(16):1489-99 doi: 10.1056/NEJMoa1501031
  18. Cannon CP,et al. Eur Heart J. 2015; May 14;36(19):1186-94.doi:10.1093/eurheart/ehv028
  19. Praluent produktresumé
  20. Peter H. Jones; Harold Bays; Umesh Chaudhari; Robert Pordy; Christelle Lorenzato; Kathryn Miller; Jennifer Robinson, J Am Coll Cardiol. 2015;65(10_S). doi:10.1016/S0735- 1097(15)61363-8
  21. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-2934.
  22. Roth EM, et al. Atherosclerosis. 2016:254;254-262